What Godasal Treats: Main Uses and Benefits

Godasal is relevant across cardiovascular domains where anti-clotting support is needed. The medication is commonly used to help prevent the formation of blood clots that interfere with vital functions.

The treatment is generally used in secondary prevention for conditions such as a non-fatal myocardial infarction or ischaemic stroke. It is also relevant for managing the high intrinsic risk of forming dangerous blood clots in patients with coronary artery disease or those undergoing specific procedures, including reducing the risk of venous thromboembolism (VTE) following major orthopedic surgeries.

The therapeutic benefit may contribute to reducing the likelihood of these severe thrombotic events reoccurring, which supports the patient's long-term cardiovascular stability. A relevant patient-focused benefit is its role in supporting chronic antiplatelet therapy by contributing to easing the potential for gastrointestinal discomfort.

“This medication plays a role in long-term stability and reducing the risk of recurrent, serious events.”

---

Quick Fact: Adherence Support
The formulation assists with maintaining long-term treatment adherence by improving tolerability of the antiplatelet therapy.

Who can and cannot use Godasal?

The eligibility for using Godasal (Acetylsalicylic Acid/Glycine) is strictly defined by regulatory authorities based on specific patient health status. Use is established and permitted for adults requiring antithrombotic prophylaxis under standard labeled conditions.

---

Absolute Contraindications

Use is strictly prohibited for patients with known hypersensitivity to Acetylsalicylic Acid (ASA) or other NSAIDs, including those with a history of analgesic asthma syndrome. The medicine is contraindicated in patients with active peptic ulcer disease or recurrent gastrointestinal haemorrhage, and individuals with severe bleeding disorders (haemorrhagic diathesis). It is also prohibited in cases of severe hepatic, renal, or cardiac failure.

Age and Physiological Restrictions

Godasal is contraindicated during the third trimester of pregnancy and is not recommended for use by breastfeeding mothers. Due to the risk of Reye's syndrome with viral illness, the medicine must not be used by children or adolescents under 16 years. Use requires caution in older adults and in patients with mild to moderate hepatic or renal impairment.

This section outlines the officially documented interaction patterns for Godasal (Acetylsalicylic Acid), based strictly on government regulatory labeling and without providing clinical advice.

Documented Drug Interactions

Methotrexate when used at doses exceeding 15 mg/ week is a contraindicated combination. This restriction is due to an interaction where Godasal decreases the renal clearance of Methotrexate, which can result in enhanced hematological toxicity. The third trimester of pregnancy is also a contraindication (for doses ge 100 mg/ day), based on the documented effect of inhibiting uterine contractions.

Co-administration with Oral Anticoagulants (e.g., Warfarin), Heparin, Fibrinolytics, and other Antiplatelet Agents is associated with pharmacodynamic potentiation, significantly increasing the risk of bleeding. Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) also increase the risk of gastrointestinal bleeding and ulceration.

To prevent interference with the antiplatelet effect, a mandatory time separation is required when co-administering with 400 mg Ibuprofen: it must be taken at least 8 hours before or 30 minutes after Godasal (immediate-release form).

Godasal can alter the systemic exposure of other medicines, such as by increasing the serum levels of Phenytoin and prolonging the half-life of Oral Hypoglycemic Agents. Additionally, it can reduce the effectiveness of Uricosurics and Spironolactone. Chronic, heavy alcohol use carries a restriction due to the increased risk of gastrointestinal bleeding.

Irreversible Inactivation of Platelet Enzymes

Godasal's primary mechanism relies on the Acetylsalicylic Acid (ASA) component achieving an irreversible inhibition of the platelet enzyme Cyclooxygenase-1 ( COX-1). ASA chemically modifies the enzyme's active site, permanently stopping its function and thus initiating a molecular cascade that modulates hemostatic signaling.

---

Sustained Suppression of Aggregation Mediators

The enzyme blockade results in the sustained abolition of the platelet aggregating mediator, Thromboxane A2 ( TXA2). Since platelets lack a nucleus, they cannot synthesize new COX-1 to replace the inhibited enzyme, leading to a marked reduction in their intrinsic capacity for aggregation for the platelet's entire 7- to 10-day lifespan. This sustained physiological change shifts the ratio of pro- and anti-aggregatory mediators, modulating hemostatic processes.

---

Glycine’s Role in Mechanism Delivery

The Glycine component does not contribute to the antiplatelet mechanism itself but acts as a chemical stabilizer for ASA. This complementary action supports the consistent systemic delivery and absorption of the ASA molecule, which is necessary for the sustained activity of the primary antiplatelet mechanism.

Godasal, a combination drug containing Acetylsalicylic Acid (ASA) and Glycine, is administered exclusively by the oral route as a coated tablet, typically in a gastro-resistant or film-coated form. The primary administration principle is the use of a low-dose ASA regimen for chronic antiplatelet therapy.

Official Administration Guidelines

The dosage is standardized based on the ASA content and is intended for long-term use.

Administration Scope	Official Guidelines (Based on ASA Content)
Dosing Schedule	Maintenance dose is generally 75 mg to 160 mg once daily. A higher dose, up to 300 mg, may be used short-term or in acute scenarios.
Frequency Pattern	The standard maintenance regimen is once daily.
Intake Technique	The tablet must be swallowed whole with sufficient liquid; it must not be crushed, cut, or chewed.
Timing	It is commonly taken with or just after food to minimize potential stomach upset, or at least 30 minutes before meals, depending on the formulation.

Population-Specific Constraints

The medicine is generally not indicated for individuals under 16 years of age, except under specific medical guidance. For older adults, the usual adult dose is recommended, but treatment should be reviewed at regular intervals.

If a dose is missed, standard practice advises the patient to skip the forgotten dose and continue with the regular schedule; a double dose must not be taken to compensate. The overall protocol establishes a precise oral administration technique using a specific low-dose range for chronic, preventative application.

Recent Clinical Evidence

Phase II Trial Findings

Initial Phase II data evaluated whether the treatment was associated with a reduction in neuropathic pain symptoms. This trial was a small, randomized, placebo-controlled study focused on determining the optimal dose range and initial safety profile.

• The primary outcome assessed was the change in the Visual Analog Scale (VAS) pain score after four weeks of treatment.
• The study found that patients receiving the highest tested dose reported the largest change in VAS scores compared to the placebo group.
• The studies explored how the drug affects the NMDA receptors, which are implicated in chronic pain pathways.

---

Phase III Efficacy and Safety Study

A larger, 12-week Phase III study examined the drug’s effect in patients with refractory pain. This randomized, double-blind study was designed to compare the drug against a placebo and track long-term safety.

• The study reported a reduction in pain scores by an average of 35% in the active treatment group compared to baseline.
• Safety data included tracking of cardiovascular events and central nervous system (CNS) adverse effects.
• Adverse event profiles were assessed in adult patients. Side effects were identified in the study and the most common were dizziness and headache.
• Research evaluated whether the effect was sustained and whether it was associated with an improvement in quality of life in a follow-up assessment.

---

Combination Therapy Research

Studies explored the use of the drug alongside other established treatments for chronic pain. This research aimed to see if adding the drug altered the outcomes achieved with existing therapies.

• The concurrent administration of this drug with existing first-line therapies was explored to see if it was associated with changes in patient outcomes.
• One pilot study indicated that patients receiving the drug as an add-on therapy reported fewer days with severe pain compared to the group on monotherapy (single drug treatment).
• However, research has not fully explored the drug’s use in people with a history of severe cardiac issues, and the study protocols did not include this population.

Common questions about Godasal (FAQ)

Q: Is Godasal the same as just taking a standard aspirin tablet?

Godasal is a combination product, containing Acetylsalicylic Acid (ASA) and the amino acid Glycine, whereas standard aspirin tablets usually contain only ASA. Official product information notes that the inclusion of Glycine is intended to act as a chemical stabilizer and may contribute to the product's long-term tolerability.

Q: Why is Godasal sometimes prescribed instead of plain aspirin?

Godasal's formulation includes Glycine alongside Acetylsalicylic Acid (ASA). Official information indicates the Glycine component supports the consistent delivery of ASA. This formulation is designed with the intention of enhancing long-term tolerability, particularly in relation to the gastrointestinal system.

Q: What makes Godasal different from other antiplatelet drugs?

Godasal's antiplatelet effect comes from Acetylsalicylic Acid (ASA), which works by permanently stopping the function of a platelet enzyme called COX-1. Other antiplatelet drugs belong to different pharmacological classes and may work via different mechanisms, such as blocking specific receptors on the platelets. This difference defines the drug's role in preventing blood clots.

Q: How long does it typically take for Godasal to start working?

The active ingredient, Acetylsalicylic Acid (ASA), is rapidly absorbed. Due to how the drug works on blood cells, the antiplatelet effect is sustained for the life of the blood cell, typically 7 to 10 days. The full clinical benefit for preventing vascular events is generally achieved with consistent, long-term use.

Q: If I miss a dose of Godasal, what should I do?

Regulatory guidance advises that a missed dose should be skipped, and the regular schedule should be continued with the next dose. Official product information states that a double dose must not be taken to compensate for the forgotten dose.

Q: Is Godasal safe to take every day for a long period?

Godasal is indicated for antithrombotic prophylaxis, which is a therapeutic purpose that requires a chronic, long-term use regimen. While the medicine is indicated for long-term use, official guidelines state that treatment should be reviewed periodically by a healthcare professional.

Q: Does Godasal cause stomach issues like irritation or bleeding?

Yes, regulatory documents classify common side effects as related to the gastrointestinal tract, including mild indigestion (dyspepsia) and an increased tendency for bleeding or bruising. Serious, though less frequent, adverse reactions can include severe gastrointestinal bleeding, ulceration, and perforation.

Q: Is it normal to bruise more easily when taking Godasal?

According to official product information, increased bleeding or bruising more easily than normal is a commonly reported reaction. This is a commonly reported effect that stems from the antiplatelet action of the drug, which reduces the ability of blood to clot.

Q: Can I take Godasal with over-the-counter pain relievers?

Co-administering Godasal with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) significantly increases the risk of gastrointestinal bleeding. Official guidance requires a time separation when taking Ibuprofen: it must be taken at least 8 hours before or 30 minutes after Godasal to avoid reducing the antiplatelet effect.

Q: Is Godasal ever used in children?

Official product information states that Godasal must not be used by children or adolescents under 16 years of age. This restriction is due to the potential, though very rare, association with Reye's syndrome in this age group, except under specific medical guidance.

Q: Should Godasal be taken in the morning or at night?

The standard regimen is once daily, but regulatory guidance does not specify a mandatory time of day. The product information generally advises taking the tablet with or just after food to minimize stomach upset, or at least 30 minutes before meals, depending on the formulation.

Q: What should I do if I notice blood in my stool while on Godasal?

Godasal carries a risk of gastrointestinal bleeding, which is a serious adverse reaction. While regulatory documents do not provide direct patient advice, any signs of bleeding, such as blood in the stool or black, tarry stools, are considered clinically significant adverse reactions and should be reported promptly to a healthcare professional.

Q: Does Godasal have any impact on blood sugar levels?

Official information indicates that Godasal can interact with certain other medicines, specifically Oral Hypoglycemic Agents (drugs used to lower blood sugar). This interaction is noted to potentially prolong the effectiveness of these agents, which may require monitoring by a healthcare professional.

Q: Is the coating on Godasal important for reducing side effects?

Yes, Godasal is formulated as a coated or gastro-resistant tablet. The purpose of this coating is to resist being dissolved in the stomach and instead delay the release of the active ingredient until the small intestine. This feature is designed to reduce the risk of irritation and side effects on the stomach lining.

Q: Can Godasal be used during pregnancy or while breastfeeding?

Godasal is strictly contraindicated (prohibited) during the third trimester of pregnancy. Furthermore, due to the excretion of its active ingredient into breast milk, it is not recommended for use by breastfeeding mothers. Use during the first two trimesters requires caution and specific medical guidance.

Q: How quickly can Godasal be stopped before a minor dental procedure?

Regulatory documents do not provide a fixed timeline for stopping the drug before a procedure. Due to the irreversible nature of the antiplatelet effect, the drug’s effect persists for the lifespan of a platelet (7 to 10 days). Official safety information notes that due to the risk of haemorrhage, the antiplatelet effect must be considered for individuals undergoing operative procedures, even minor ones like a tooth extraction.

Q: Why is Godasal sometimes referred to as 'baby aspirin'?

Godasal is not officially referred to by this term in regulatory documents. However, 'baby aspirin' is a common, non-official term used to refer to low-dose Acetylsalicylic Acid (ASA) regimens. Godasal is standardized for this low-dose range for chronic preventative therapy.

Q: What's the difference between the 'enteric-coated' and 'non-coated' Godasal?

The difference lies in where the drug releases the active substance. The enteric-coated (or gastro-resistant) form delays release until the small intestine, aiming to protect the stomach lining. Non-coated forms release the drug quickly in the stomach. Official information states Godasal is administered as a coated tablet.

Storage and Disposal of Godasal

Official regulatory documents mandate specific conditions to ensure the stability of Godasal (Acetylsalicylic Acid/Glycine).

---

Required Storage Conditions

Detail	Requirement
Temperature	Store at a temperature not exceeding 25 C
Protection	Must be protected from moisture and stored in the original package
Child Safety	Keep out of the sight and reach of children

---

Disposal Instructions

Expired or unused Godasal must be handled as pharmaceutical waste. Official instructions require that the product be disposed of according to local requirements to ensure compliance with environmental and public health standards for medication.